Hayley Virgil

Serplulimab, which has been granted orphan drug designation by the FDA, is being considered as a treatment for patients with small cell lung cancer.

Although patients with endometrial cancer who had histologically confirmed endometriosis/adenomyosis achieved better overall survival than those without, the benefit was linked to stage, grade, age, and histological subtype.

Black patients were reported to be significantly less likely to receive standard of care surgical treatment for cancer of the gastrointestinal tract compared with White patients.

Patients with HER2-positive apocrine carcinoma of the breast are less likely to have an aggressive phenotype and are more likely to have favorable outcomes, even though the group has a lower rate of estrogen and progesterone receptor positivity.

The phase 1/2a TakeAim Leukemia trial assessing emavusertib alone or with azacitidine or venetoclax in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndrome has been placed on a partial clinical hold by the FDA.

In an interview with CancerNetwork®, Melissa Hardesty, MD, discusses how maintenance niraparib and bevacizumab following frontline platinum-based chemotherapy and bevacizumab yielded promising results in patients with advanced ovarian cancer.

Although tiragolumab plus atezolizumab and chemotherapy missed the primary end point of progression-free survival superiority in the phase 3 SKYSCRAPER-02 trial in patients with extensive-stage small cell lung cancer, it will continue to be evaluated in non–small cell lung cancer.

In an interview with CancerNetwork® during National Colorectal Cancer Awareness Month, Rachel Pearlman, MS, LGC, highlights recent updates in genetic testing in colorectal cancer and where the field needs to head to provide individuals with better options.

Patients with locally advanced cervical cancer did not see further benefit from the addition of concurrent durvalumab to chemoradiotherapy.

A biologics license application for sintilimab plus chemotherapy in first-line nonsquamous non–small cell lung cancer was not approved by the FDA and a complete response letter was issued to the drug developer.

Findings from a meta-analysis indicated that pathologic complete response is a notable predictor of outcomes in HER2-positive breast cancer.

Survival among patients with multiple myeloma appears to be influenced by factors such as socioeconomic status and treatment facility type.

Maurie Markman, MD, sits down with CancerNetwork® to discuss proposed legislation that would put a time limit on how long drugs with an accelerated approval can stay on the market, and how that may negatively impact patients with cancer.

Patients with mantle cell lymphoma appeared to benefit from brexucabtagene autoleucel as salvage therapy in the real-world setting.

A survival benefit was observed in patients with advanced or recurrent endometrial cancer who were treated with maintenance selinexor.

Patients with pretreated ovarian cancer who are resistant to platinum-based chemotherapy may experience promising responses and disease control following treatment with nemvaleukin alfa and pembrolizumab.

No differences in overall and progression-free survival were observed at the GOG-0252 trial update among patients with ovarian cancer who were treated with intravenous or intraperitoneal chemotherapy plus bevacizumab.

Patients with unresectable or metastatic melanoma can now receive treatment with nivolumab and relatlimab-rmbw following its approval by the FDA.

Patients with untreated metastatic or unresectable melanoma experienced numerically improved overall survival and response rates as well as long-lasting progression-free survival benefit following treatment with nivolumab and relatlimab.

In recognition of Kidney Cancer Awareness Month, CancerNetwork® spoke with Laurence Albigès, MD, PhD, about immunotherapy combination trials for renal cell carcinoma that read out at the 2022 Genitourinary Cancers Symposium.

Axillary ultrasound and biopsy appear to be an effective strategy to identify nodal disease in patients with early-stage triple-negative breast cancer.

A phase 1 study of davoceticept and pembrolizumab for advanced malignancies received a partial clinical hold from the FDA following a patient death.

Pediatric patients with newly diagnosed pediatric T-cell lymphoblastic lymphoma experienced an improvement in survival following treatment with bortezomib and chemotherapy.

Applications for darolutamide were submitted to the FDA and European Medicines Agency for the treatment of patients with non-metastatic hormone-sensitive prostate cancer.

The phase KEYNOTE-716 trial, which assessed the use of adjuvant pembrolizumab in patients with resected stage IIB and IIC melanoma, met its secondary end point of distant metastasis-free survival.

Post-resection survival could be predicted by FAM46C expression in patients with gastric adenocarcinoma.

A supplemental new drug application for ivosidenib plus azacitidine was granted priority review by the FDA for previously untreated patients with IDH1-mutant acute myeloid leukemia.

NUC-1031 plus cisplatin was unlikely to reach a primary end point of improved overall survival in advanced biliary tract cancer, leading to the discontinuation of the phase 3 NuTide:121 trial.

A clinical hold has been placed on the phase 1b CYAD-101-002 trial, examining pembrolizumab after treatment with CYAD-101 and folinic acid, fluorouracil, and oxaliplatin preconditioning in metastatic colorectal cancer.

Following a submission of updated survival data, the FDA has extended the Prescription Drug User Fee Act date for ublituximab/umbralisib in chronic lymphocytic leukemia and small lymphocytic lymphoma.